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Abstract
Background: There is growing evidence that DNA methylation alterations may contribute to carcinogenesis.
Recent data also suggest that DNA methylation field defects in normal pre-neoplastic tissue represent infrequent
stochastic “outlier” events. This presents a statistical challenge for standard feature selection algorithms, which
assume frequent alterations in a disease phenotype. Although differential variability has emerged as a novel feature
selection paradigm for the discovery of outliers, a growing concern is that these could result from technical
confounders, in principle thus favouring algorithms which are robust to outliers.
Results: Here we evaluate five differential variability algorithms in over 700 DNA methylomes, including two of the
largest cohorts profiling precursor cancer lesions, and demonstrate that most of the novel proposed algorithms lack
the sensitivity to detect epigenetic field defects at genome-wide significance. In contrast, algorithms which
recognise heterogeneous outlier DNA methylation patterns are able to identify many sites in pre-neoplastic lesions,
which display progression in invasive cancer. Thus, we show that many DNA methylation outliers are not technical
artefacts, but define epigenetic field defects which are selected for during cancer progression.
Conclusions: Given that cancer studies aiming to find epigenetic field defects are likely to be limited by sample
size, adopting the novel feature selection paradigm advocated here will be critical to increase assay sensitivity.
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Background
Feature selection presents an important statistical chal-
lenge in the analysis of omic data [1–3]. It is most often
encountered in the context of supervised analyses where
one wishes to find features that are informative of differ-
ences between two phenotypes of interest (POI). The
standard paradigm is to identify features for which the
average level of the molecular mark of interest (e.g. DNA
methylation or gene expression) is significantly different
between two POI, using well-known tests such as Stu-
dent’s t-test, its regularized/moderated versions [4–6], or
non-parametric equivalents such as the Wilcoxon rank
sum (or Mann–Whitney) test [7]. However, an often over-
looked problem when applying t-tests, or their non-
parametric equivalents, to omic data, is that these tests
are underpowered to detect biological outliers, i.e. infre-
quent (heterogeneous) changes of considerable magni-
tude, which occur mainly, if not exclusively, within one
phenotype. A number of recent studies have highlighted
the potential importance of such heterogeneous, stochas-
tic, outlier events in disease aetiology [8–15]. For instance,
one study measured DNA methylation in precursor cer-
vical cancer samples and showed that DNA methylation
outliers in these cytologically normal lesions were predict-
ive of progression to neoplasia [13]. It is therefore entirely
plausible that such DNA methylation outliers may, in gen-
eral, define epigenetic cancer field defects [16–18], i.e. mo-
lecular alterations in normal cells which later undergo
neoplastic transformation.
Given that t-tests and other standard statistical tests
are unsuitable for identifying epigenetic outliers, we pro-
posed a novel feature selection paradigm based on the
concept of differential variability (DV) [13, 14]. A grow-
ing concern however is that outliers could in principle
also reflect genetic and technical factors [19]. Because of
this, a number of DV tests have emerged, with improved
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statistical properties, notably with an improved control
of the type-1 error rate [19–21]. As pointed out by these
studies, if differentially variable outliers were technical
artefacts, then certain DV tests such as Bartlett’s test (or
F-test) would suffer from a very high type-1 error rate.
On the other hand, given that cancer studies profiling
precursor lesions are generally limited by sample size,
DV tests which exhibit good control of the type-1 error
rate, may also be seriously underpowered to detect the
biologically interesting outliers.
Henceforth, we here conduct a detailed comparison of
five different DV algorithms on a total of five DNA
methylation data sets, encompassing over 700 samples,
including two of the largest studies profiling precursor
cancer lesions [13, 22]. We demonstrate marked vari-
ation in the ability of DV algorithms to identify true
positives, with deep and far-reaching implications for
studies seeking to identify epigenetic field defects in can-
cer and possibly also in other complex diseases.
Methods
DNA methylation datasets
We analysed a total of 5 DNA methylation data sets (see
Additional file 1: Table S1 for summary).
Precursor and cancer DNA methylation datasets
Our primary DNA methylation data sets focused on the
profiling of precursor cancer lesions and are available
from the GEO website (www.ncbi.nlm.nih.gov/geo/)
under accession numbers GSE30758 and GSE69914.
Dataset GSE30758 consists of 152 cytologically normal
cervical smear samples, representing prospectively col-
lected samples within the ARTISTIC trial, with 75 of the
women who provided a sample developing a cervical
intraepithelial neoplasia of grade 2 or higher (CIN2+)
three years after sample collection [13]. In order to test
whether CpGs identified from GSE30758, i.e. CpGs that
correlate with the risk of CIN2+, show more progressive
changes in CIN2+ and cervical cancer we used three
other data sets (GSE20080, GSE37020, GSE30759) pro-
filing normal cervical and CIN2+ or cervical cancer sam-
ples (Additional file 1: Table S1). All of these datasets
were generated using Illumina Infinium 27 k beadarrays
and we used the normalized data, as described by us
previously [13, 14].
Dataset GSE69914 was generated using Illumina Infi-
nium 450 k beadarrays and consists of 50 normal breast
tissue samples from healthy women, a set of 42 matched
normal-adjacent breast cancer pairs (a total of 84 sam-
ples), and a further 263 unmatched breast cancers. Raw
data was processed with minfi [23] using the preprocess-
Raw function, the Illumina definition for methylation
signal in getBeta and estimating P-values of detection
with detectionP using total intensity “m+ u”. Type-2
probe bias was corrected using BMIQ [24]. Subse-
quently, we tested for batch effects by performing a SVD
on the intra-sample normalized data matrix, and check-
ing which factors (biological or technical) the top com-
ponents of variation were correlating with. The top
components of variation in this data matrix correlated
with biological factors, notably normal-cancer status.
Statistical algorithms for differential variability (DV)
We compared a total of 5 algorithms/statistical tests,
aimed at identifying differentially variable features. The
five DV algorithms/tests are (i) Bartlett’s test [25], (ii) a
novel DV algorithm, which we call “iEVORA” (similar to
the original EVORA-Epigenetic Variable Outliers for
Risk prediction Analysis algorithm [13, 14] ), (iii) a joint
test for differential means and differential variance in
DNA methylation (“J-DMDV”) [20], (iv) an empirical
Bayes Levene-type test (“DiffVar”) [19] and (v) a test
based on a generalized additive model for location and
scale (“GAMLSS”) [21]. With the exception of iEVORA,
which we present here for the first time, all other DV al-
gorithms (i.e. BT/EVORA, J-DMDV, DiffVar, GAMLSS)
have been previously used in cancer epigenome or
EWAS studies [13, 21, 26].
BT & iEVORA
Briefly, Bartlett’s test (BT) is similar to an F-test for testing
homoscedasticity, and is well-known to be sensitive to sin-
gle outliers. Because of this, we also consider a regularized
version of it, which we call iEVORA, whereby features
deemed significant by Bartlett’s test are re-ranked accord-
ing to an ordinary differential methylation statistic (e.g.
the statistic from a t-test). To clarify this further, P-values
from Bartlett’s test are used to estimate corresponding
false discovery rate (FDR) values using the Q-value
method [27] and a threshold (typically FDR < 0.05) used to
select significantly DV features. These significantly DV
features are then re-ranked according to their differential
methylation statistic. Thus, in iEVORA, significance is
assessed at the level of differential variability, using
Bartlett’s test, but significant DV features with larger
changes in the average DNA methylation are favored over
those with smaller shifts in average DNA methylation.
This re-ranking strategy therefore ensures that DV fea-
tures driven by single, or a few, outliers are only ranked
highly if there are no features which are differentially
methylated in terms of mean DNAm levels.
J-DMDV, DiffVar and GAMLSS
The third algorithm (“J-DMDV”), proposed by Wang
and Ahn [20], works in the M-value (M = log2[β/(1-β)]
basis and uses a joint score test for mean and variance
within a linear regression framework. P-values from this
test are converted into Q-values (FDR) and features
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selected (and also ranked) according to a FDR < 0.05
threshold. The fourth algorithm (“DiffVar”) is based on
an empirical Bayes extension of the Levene-test [19].
Briefly, this algorithm first computes the square (or ab-
solute) deviations of samples within a phenotype from
the corresponding group (phenotype) mean using the
M-value basis. It then uses the framework of moderated
t-tests [5], to compare the distribution of deviations be-
tween the two phenotypes. P-values from this test are
converted into Q-values (FDR) and features selected
(and also ranked) according to a FDR < 0.05 threshold.
The final algorithm (“GAMLSS”) was developed by
Wahl et al. [21] within the GAMLSS (Generalized
Additive Models for Location, Scale and Shape) frame-
work. This algorithm also works in the M-value basis,
and here we adapt it to run on 3 separate generalized
linear additive models within a nested framework: a null
model without mean and variance, a regression model
for the mean only and a model for the mean and vari-
ance. Two likelihood ratio tests are then constructed by
comparing the log-likelihoods of the mean-only model
to the null, and the mean + variance model to the mean-
only model. This yields two P-values for each feature,
and features are deemed significant if at least one of
these two P-values is less than a nominal threshold (after
adjustment for multiple testing using a FDR < 0.05
threshold). Thus, GAMLSS will yield significant hits if
there are differences in terms of mean DNAm. We also
note that our implementation of GAMLSS does not
compare a variance-only model to the null, since the al-
gorithm aims to identify additional features where vari-
ance “adds predictive value” over a model which only
includes the mean.
Software availability (iEVORA)
The iEVORA algorithm is freely available as an executable
R-script, and can be found as a Supplementary Software
file as part of the accompanying publication, see [22].
Evaluation of DV algorithms to detect true DVCs on
simulated data
In order to compare the DV algorithms to each other,
we devised a simulation framework allowing also for
different types of differential variability. In each simula-
tion run we generated an artificial DNA methylation
data matrix consisting of 6000 CpGs and 100 samples.
Samples were subdivided into two phenotypes, a “nor-
mal” and a “disease state”, each comprising 50 samples.
We declared 600 CpGs to be truly differentially variable,
allowing for 3 different types of DV, with 200 CpGs in
each type. The remaining 5400 CpGs are not differen-
tially variable. These are modelled from a beta-value dis-
tribution B(a1,b1) with a1 = 10 and b1 = 90, i.e. we
assume that these CpGs are generally unmethylated with
a mean beta value of 0.1, with a standard deviation of ap-
proximately +/− 0.03. For the 600 true positives, a propor-
tion of the samples in the “disease” phenotype are modelled
from a beta-value distribution B(a2,b2) with a2 = 6
and b2 = 4, i.e. a distribution with mean value 0.6 and a
standard deviation of approximately +/− 0.15. We note that
although in this simulation we consider all CpGs to be
unmethylated in the normal state, that there is no loss of
generality, since mathematically, there is a complete sym-
metry between unmethylated and methylated CpGs. Thus,
for the 600 true DVCs and for a number of samples in the
disease phenotype, there will be an average increase in
DNAm of ~0.5. The 600 true DVCs however fall into 3 cat-
egories of DV. For 200 of these CpGs, we model all samples
in the disease phenotype from B(a2,b2). Thus, these DVCs
will typically also differ in terms of the mean level of DNA
methylation and in fact, will exhibit stronger differences in
terms of the mean DNAm than in terms of differential vari-
ance. Hence, these 200 DVCs are of “type-1a” DV. For an-
other 200 CpGs, we only allow 20 of the 50 disease
phenotype samples to be modelled from B(a2,b2), with rest
of the samples being modelled from B(a1,b1). Thus, for
these DVCs, half of the disease samples exhibit increases in
DNAm, with the rest being indistinguishable from the nor-
mal phenotype. For these CpGs, differential variance is the
key discriminatory characteristic, although they will still ex-
hibit significant differences in terms of mean DNAm since
a reasonable fraction of the disease samples exhibit devia-
tions from the normal state. These DVCs are of “type-1b”
differential variability. Finally, for the last set of 200 true
positives, we only allow 3 disease samples to differ from the
normal state. For these DVCs, there is therefore no signifi-
cant difference in terms of the average DNA methylation
between the two phenotypes. However, the variance will
differ owing to the outliers in the disease phenotype. These
DVCs are defined as being of “type-2”.
We performed a total of 100 Monte Carlo runs, in each
run recording 5 performance measures for each of the five
DV algorithms: (1) the overall sensitivity of the DV algo-
rithm using a FDR (false discovery rate) corrected thresh-
old of 0.05, defined as the fraction of true DVCs identified
by the DV algorithm, (2) the true FDR at the estimated
FDR < 0.05 threshold where the FDR estimate was ob-
tained using Q-values [27], (3–5) the sensitivities to detect
type-1a, type-1b and type-2 differentially variable CpGs.
We focused on the FDR and not the FPR (false positive
rate), since it is the FDR which gives us the confidence
level that a given positive is a true positive, i.e. the FDR is
related to the positive predictive value (PPV) through the
relation FDR = 1-PPV.
Evaluation of DV algorithms on real DNA methylation data
Initially, we compared the algorithms in their ability to
detect DVCs between normal samples from healthy
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women and normal samples from women who devel-
oped neoplasia or who had cancer (see section on
DNAm data sets for details), without considering the
likelihood of these DVCs being true positives. Thus, for
each of the DV algorithms and each CpG site, we esti-
mated P-values, and from these, Q-values (FDR) [27]. In
the case of BT and iEVORA, P-values came from
Bartlett’s test. In the case of DiffVar and J-DMDV, both
tests provide P-values, as described in the respective
publications. Features were deemed significant if Q <
0.05. In the case of GAMLSS, we obtained two P-values,
one assessing whether the mean is associated with the
phenotype, and another assessing whether the variance
adds predictive value over the mean. Both sets of P-
values were transformed into Q-values and features with
at least one of these Q-values being less than 0.05, were
selected and deemed statistically significant.
To enable a more formal comparison of the DV algo-
rithms, we devised a strategy that would allow us to esti-
mate the positive predictive value (PPV) of the test. The
key insight or hypothesis is that DVCs obtained in the
discovery set are more likely to be biological true posi-
tives if they exhibit progressive changes in DNA methy-
lation in either neoplastic or invasive cancer tissue. A
feature detected in pre-neoplastic lesions (i.e. in the dis-
covery set) that is biological relevant is more likely to
mark cells which become neoplastic and therefore one
would expect enrichment of these marks in neoplasia
and invasive cancer. This means that if a given “true
positive” CpG site exhibits higher DNAm levels (maybe
only marginally so) in precursor cancer lesions, that this
same site will undergo larger and more frequent DNAm
changes in cells that are neoplastic or invasive. Thus, the
PPV refers to the fraction of CpGs identified in the dis-
covery set (i.e. by comparing normal cells at risk of neo-
plastic transformation to normal cells that are not at
risk), which exhibit progression in the independent data
sets representing the more advanced stage in cancer de-
velopment. Statistically, this “progression” can be mea-
sured using t-statistics from a t-test, since the t-statistic
is proportional to the average deviation in DNAm from
the normal state. A similar argument can be applied to
the case of CpG sites that undergo marginal hypomethy-
lation in precursor cancer lesions.
In the context of cervical carcinogenesis, we thus ap-
plied the DV algorithms to identify DVCs hypervariable
in the 75 normal samples which 3 years later progressed
to CIN2+ status compared to the 77 normal samples
from women who remained healthy (the “ART” data set
in Additional file 1: Table S1). The DNAm data for this
set were generated on Illumina 27 k beadarrays, and so,
because of the design of the 27 k array, we only focused
on DVCs which exhibited increases in DNAm in the
precursor lesions. We considered the top ranked 500,
1000 and 5000 DVCs (irrespective of FDR values attain-
ing statistical significance). In the case of GAMLSS,
which provides two P-values per feature, we ranked the
selected features according to the significance of the DV
statistic. For each DV algorithm, we then computed and
compared t-statistics of these top ranked DVCs in two
independent Illumina 27 k data sets profiling normal
and CIN2+ samples, and another 27 k dataset of normal
cervix and cervical cancers (“CIN2 + (A)&(B)” and “CC”
in Additional file 1: Table S1). The fraction of DVCs
attaining t-statistics larger than 1.96 (P < 0.05) and pre-
serving the same directionality of change in the inde-
pendent data was used as the PPV estimate. We note
that although using a P < 0.05 in the independent data
set does not correct for multiple-testing of 500, 1000 or
5000 features, that in this context it is more important
to control the false negative rate (FNR). In other words,
using an overly stringent significance threshold in the in-
dependent data would lead to an unnecessarily large
FNR. Moreover, the same criterion is used for each
method.
In the context of breast carcinogenesis, we applied the
DV algorithms to identify DVCs hypervariable in the 42
normal-adjacent samples compared to the 50 normal sam-
ples from healthy women. Because of the design of the
450 k array, we now considered DVCs which exhibited ei-
ther increases or decreases in DNAm in the normal-
adjacent samples. We considered the top ranked 500, 1000
and 5000 DVCs in each category (irrespective of FDR values
attaining statistical significance). In each case, we then com-
puted t-statistics of these top ranked CpGs, as derived from
comparing the 50 normal breast tissue samples to 305
breast cancers. The fraction of DVCs attaining t-statistics
larger (lower) than 1.96 ( −1.96) (P < 0.05) and preserving
the same directionality of change in the independent data,
was used as the PPV estimate. As before, this threshold en-
sures a reasonable compromise between the FDR and FNR.
Results
DV algorithms that have strong control for the type-1
error rate do not identify differentially variable CpGs
(DVCs) in studies profiling precursor cancer lesions
Our overall strategy is summarized in Fig. 1. Briefly, we se-
lect two DNA methylation data sets comparing normal
cells from healthy individuals to normal cells which either
become neoplastic a few years later (Cervix-study), or
which were collected adjacent to a breast cancer (Breast-
study). We compare DV algorithms in their ability to iden-
tify DVCs between these two normal phenotypes (Fig. 1a).
To assess whether the DVCs are biological, i.e. whether
they define putative field defects, we ask if these DVCs ex-
hibit progression/enrichment within established neoplastic
tissues (Fig. 1b). This strategy allows us to compare DV
algorithms in their ability to detect field defects.
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We decided to compare a total of 5 DV algorithms,
with four of these having been proposed recently: (i)
Bartlett’s test (BT) [13], (ii) a joint test for differential
means and differential variance in DNA methylation (“J-
DMDV”) [20], (iii) an empirical Bayes Levene-type test
(“DiffVar”) [19] and (iv) a test based on a generalized
additive model for location and scale (“GAMLSS”) [21].
As previously shown, Bartlett’s test is highly sensitive to
single outliers [19–21], and assuming that single outliers
are not of biological interest, this translates into a poor
control of the type-1 error rate. Thus, the recently pro-
posed J-DMDV, GAMLSS and DiffVar algorithms offer
improved control of the type-1 error rate [19–21]. In
addition to these 4 tests, we here devised a novel DV al-
gorithm, which we call “iEVORA” (Methods), similar to
the original EVORA (Epigenetic Variable Outliers for
Risk prediction Analysis) algorithm [13, 14], and which
can be thought of as providing a regularized version of
Bartlett’s test.
We first applied each of these five DV algorithms, as
well as moderated t-tests, to a data set (“ARTISTIC”)
which had profiled 152 cytologically normal cervical
smear samples with Illumina 27 k DNA methylation
beadarrays, with 75 of these 152 samples being from
women who three years after sample collection devel-
oped a high grade cervical intraepithelial neoplasia
(CIN2+) [13]. We note that there were no genome-wide
significant differentially methylated CpGs (DMCs) be-
tween the normal samples from women who remained
disease-free and the normal samples which progressed
Fig. 1 Overall strategy for comparing DV algorithms in their ability to identify field defects in cancer: a In a discovery step, we apply five DV
algorithms (BT, iEVORA, GAMLSS, J-DMDV, DiffVar) to identify differentially variable CpGs (DVCs) between two normal phenotypes, in two tissue
types, as shown. The DV algorithms differ in their sensitivity and control of type-1 error rate, with some DV algorithms not identifying stochastic
outlier profiles (i.e. DNA methylation profiles with a few outliers), whilst others are sensitive to them. b In the validation step, we assess the identified
DVCs (if any) of each DV algorithm in terms of whether they exhibit progression/enrichment within established neoplastic cells or invasive cancers. This
allows an objective comparison of the DV algorithms and helps assess whether stochastic epigenetic outliers identified in step-A using algorithms such
as iEVORA are biological or not
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to CIN2+, as assessed using moderated t-tests (Table 1,
Fig. 2a), in agreement with our previous observation
[13]. We next compared all five DV algorithms in their
ability to detect differentially variable CpGs (DVCs) be-
tween the same two phenotypes. We observed marked
differences, with J-DMDV and DiffVar not identifying
any DVCs at genome-wide significance, in stark contrast
to iEVORA and GAMLSS which could identify many
DVCs (Table 1, Fig. 2a). On the other hand, if we com-
pared normal to CIN2+ samples, or normal samples to
cervical cancer, we observed many DMCs and all DV al-
gorithms had enough sensitivity to identify DVCs
(Table 1).
The algorithms performed similarly in a second data
set, measuring DNA methylation (now Illumina 450 k
beadarrays) in over 300 samples, including 50 normal
breast tissue samples from healthy women, 42 normal-
adjacent breast tumor matched pairs and an additional
263 unmatched breast cancers (Methods). In this inde-
pendent set we could also not detect any DMCs between
the normal cells from healthy women and the normal
cells adjacent to breast cancers (Table 1, Fig. 2b). The
two DV algorithms which in the cervical smear analysis
could not identify any DVCs, could also not identify any
DVCs in this set (J-DMDV), or in the case of DiffVar,
not as many as GALMSS or iEVORA (Table 1, Fig. 2b).
In agreement with the cervical study, if we compared
the normal samples from healthy women to breast can-
cers, we observed that most sites in the genome consti-
tuted DMCs, as well as DVCs, and that any DV
algorithm could identify DVCs (Table 1).
DVCs pinpoint epigenetic field defects which progress to
invasive cancer
The increased sensitivity of iEVORA and GAMLSS to
detect DVCs in pre-neoplastic lesions does not necessar-
ily mean that these DVCs are biological features of rele-
vance to the carcinogenic process. However, if DVCs
detected between normal and pre-neoplastic lesions
exhibit progressive changes in neoplasia and invasive
cancer, then this would support their biological rele-
vance. Thus, we compared all the algorithms in their
ability to detect CpG sites in pre-neoplastic lesions,
which later progress in neoplasia and/or invasive cancer
(Methods). In the context of cervical carcinogenesis,
progression was assessed using two independent data
sets profiling normal and CIN2+ samples, as well as a
data set profiling normals and invasive cervical cancers
[14]. We observed that DVCs selected and ranked using
iEVORA, Bartlett’s test (BT) or GAMLSS were more
likely to undergo further significant DNAm changes
(preserving directionality) in CIN2+ and cervical cancer
compared to features selected using t-tests, or one of the
other DV algorithms (J-DMDV and DiffVar) (Fig. 3,
Additional file 1: Figures S1-S2). iEVORA was more ro-
bust than BT and GAMLSS, attaining positive predictive
values (PPV) for CIN2+ of over 25 % and for cervical
cancer of over 60 % across a larger range of top ranked
DVCs (Fig. 3).
iEVORA also outperformed all other DV algorithms in
the context of breast carcinogenesis, where progression
was assessed by comparing the 50 normal breast samples
from healthy women to the 305 breast cancers. In most
cases, iEVORA achieved PPVs for breast cancer of
around 80 % or over, in stark contrast to BT or
GAMLSS, whose PPVs never exceeded 40 % (Fig. 4a,
Additional file 1: Figure S3).
To further demonstrate the biological relevance of
DVCs in breast cancer progression, we selected the top
ranked 500 DVCs (using iEVORA) between the 50 nor-
mal breast samples and the 42 normals adjacent to
breast cancers and further compared their DNA methy-
lation values in the 42 matched breast cancers. This
showed that approximately 80 to 86 % of the DVCs
which were hypermethylated in normal-adjacent tissue
(compared to normals from healthy women), exhibited
additional DNAm increases in the matched breast can-
cers (Fig. 4b). A similar pattern was observed for the
Table 1 Comparison of Differential Variability (DV) and t-test feature selection algorithms on DNAm data
Feature selection algorithm CIN2+ risk (27 k) CIN2+ (27 k) CC (27 k) NADJ (450 k) BC (450 k)
Moderated t-tests 0 2456 (10 %) 13009 (50 %) 0 345479 (71 %)
Bartlett-test (BT) 1584 (7 %) 3475 (15 %) 17846 (69 %) 99913 (21 %) 400689 (82 %)
IEVORA 1584 (7 %) 3475 (15 %) 17846 (69 %) 99913 (21 %) 400689 (82 %)
DiffVar 0 202 (<1 %) 8928 (35 %) 2051 (<1 %) 268027 (55 %)
J-DMDV 0 1973 (8 %) 11632 (45 %) 0 416995 (86 %)
GAMLSS2 1045 (4 %) 3263 (14 %) 16626 (64 %) 37106 (<1 %) 434657 (89 %)
The rows label the name of the feature selection algorithm, the number of identified features associated with different phenotypes at an FDR < 0.05. The
phenotypes considered are prospective risk of CIN2+ (i.e. precursor CIN2+ lesions, n = 75), CIN2+ (cervical intraepithelial neoplasia of grade 2 or higher, n = 24), CC
(cervical cancer, n = 48), normal breast tissue adjacent to a breast cancer (NADJ, n = 42), and breast cancer (BC,n = 305). In the context of the cervix, the reference
phenotype were normal cervical samples profiled in each study (n = 77, 24 and 15, respectively). In the context of breast, the reference were 50 normal breast
tissue samples from healthy women. We note that since Bartlett’s-test and IEVORA only differ in the ranking order of significant features, that their values here are
identical. In boldface we indicate the algorithm(s) identifying most DVCs in each of the two normal-to-normal comparisons
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case of DVCs that were hypomethylated in normal-
adjacent tissue, although the association was less striking
(Fig. 4b). Together, these results demonstrate that
iEVORA is able to identify epigenetic field defects which
exhibit further progressive changes in breast cancer.
Types of DV in DNA methylation and their dynamics in
carcinogenesis
Next, we sought to understand why there are such
marked differences among DV algorithms to detect
DVCs in the earliest stages of carcinogenesis, whilst dif-
ferences are less marked in later stages (Table 1). Based
on extensive data analysis of DNA methylation datasets
[13], we first categorized DV into 3 broad classes (Fig. 5,
Methods). We define “type-1 DVCs” as those which also
differ significantly in terms of average DNA methylation
levels (Fig. 5a), with a further subdivision into “type-1a”
and “type-1b” depending on whether the DVCs exhibit
stronger differences in the mean or variance (Fig. 5a). In
contrast to type-1 DVCs, type-2 and type-3 DVCs only
show differences at the level of DNAm variance, with
average levels of DNAm in each phenotype being statis-
tically indistinguishable (Fig. 5a). The key difference be-
tween type-2 and type-3 DVCs is that in the type-2 case,
the increased variance is driven by few outliers exhibit-
ing coordinated changes (i.e. in the same direction),
whereas in the type-3 case, the increased variance is po-
tentially due to more outliers but with a larger level of
discoordination, with outliers exhibiting both hyper and
hypomethylation (Fig. 5a). Real data examples confirm
the existence of these different types of DV (Fig. 5b),
and although most of these focus on hypermethylation,
analogous types of DV exhibiting hypomethylation are
also observed (Additional file 1: Figure S4).
Demonstrating that this taxonomy of DV is of bio-
logical relevance, we observed that DVCs typically ex-
hibited progressive changes in DNA methylation in
carcinogenesis, evolving from being type-2 DVCs in the
earliest stages of cancer to being type-1 DVCs in neopla-
sia (Fig. 6a, Additional file 1: Figure S5). Confirming this
dynamics of DV on a global scale, we observed that
type-1 and type-2 DV exhibited widely different frequen-
cies depending on disease stage, with type-1 DV being
very infrequent in pre-neoplastic lesions but much more
prominent in neoplasia and invasive cancer (Fig. 6b).
Thus, we posited that the variable performance of DV
algorithms and the critical dependence on disease stage,
could be explained by their varying sensitivities to detect
different types of DV. To this end, we conducted a simu-
lation study, where we simulated DVCs from the type-
1a, type-1b and type-2 subtypes, and then compared the
sensitivity of the different algorithms to detect them
Fig. 2 Sensitivity to detect field defects in cancer: a Histograms of P-values of five feature selection methods (as indicated) in the ARTISTIC data
set comparing 75 cytologically normal samples which do not progress to CIN2+ and 77 cytologically normal cells which do progress to CIN2+
within 3 years. b As (a) but now for the PRE-BC data set comparing 50 normal breast samples from healthy women to 42 normal-adjacent
samples from age-matched breast cancer patients
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(Methods). We observed that Bartlett’s test, iEVORA
and GAMLSS were able to retrieve all types of true
DVCs with equal power without losing much control of
the false discovery rate (FDR) (Fig. 6c). In contrast, al-
though J-DMDV and DiffVar could achieve much better
control of the FDR, their power to detect type-2 DV was
clearly compromised (Fig. 6c).
Outlier DVCs are not markers of immune or stromal cells,
but are enriched for transcription factor binding sites and
PRC2/bivalent target genes
In principle, one could argue that outlier DVCs are the
result of alterations in tissue composition caused by
changes in stromal or immune-cell infiltrates. If so, we
reasoned that a Gene Set Enrichment Analysis (GSEA)
would reveal enrichment of biological terms related to
stromal or immune cell-types [28–30]. Performing a
GSEA using an expanded Molecular Signatures Database
(MSigDB) [31], which included sets of transcription factor
binding sites, as implemented by us previously [22, 32],
we did not observe however any evidence for enrichment
of stromal or immune-cell type terms among hypervari-
able DVCs (Additional file 2). In fact, hypervariable DVCs
only exhibited a strong enrichment for bivalently marked
genes and binding sites of transcription factors specifying
chromatin architecture, including PRC2, RAD21 and
CTCF (Additional file 1: Table S2 and Additional file 2:
Table S2). Thus, together, these results support the view
that changes in the stromal/immune cell composition of
the normal tissues are not driving the specific outlier
DVCs as identified using iEVORA.
Outlier DVCs are underenriched for cross-reactive and
polymorphic probes
If outlier DVCs are biological features, marking cancer
field defects, we reasoned that these DVCs would also
be underenriched for probes that have been deemed to
be cross-reactive or polymorphic [33]. Indeed, focusing
on the 99913 DVCs identified using iEVORA in the
breast tissue study (Fig. 2b), we observed an overlap of
17206 CpGs with the 93382 cross-reactive and poly-
morphic probes of Chen et al. [33], representing an
Odds Ratio (OR) overlap of 0.60, representing a signifi-
cant underenrichment (one-tailed Fisher-test, P < 1e-50).
Equivalently, by random chance, the overlap should have
been around 19217 (Binomial test P < 1e-58). Restricting
to the top 5000 hypervariable and hypermethylated
DVCs of iEVORA, the overlap was 369 with an
Fig. 3 Positive Predictive Values (PPVs) of DVCs identified from pre-neoplastic lesions in cervical neoplasia and invasive cervical cancer. a PPVs of
differentially variable CpGs (DVCs) selected by each of five different DV algorithms from the ARTISTIC data set (comparing 75 normal cervical
smear samples from women who 3 years later developed a CIN2+ to 77 from women who remained disease free), with the PPV values estimated
in an independent Illumina 27 k set profiling 24 normal cervical smears (N) and 24 CIN2+ samples. The number of top-ranked selected DVCs
increases along the panels from left to right. The PPV was estimated as the fraction of hypermethylated DVCs attaining a t-statistic larger than
1.96 (P < 0.05) in the independent set. Only hypermethylation was considered due to the design of the 27 k beadarray which is overrepresented
for probes in gene promoters. b As (a), but now for an independent Illumina 27 k set profiling 15 normal cervical tissue (N) and 48 invasive
cervical cancers (CC)
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Fig. 4 Positive Predictive Values (PPVs) and progression of DVCs from normal-adjacent tissue in invasive breast cancer. a PPVs of differentially variable
CpGs (DVCs) selected by each of five different DV algorithms from comparing 50 normal breast samples from cancer-free women to 42 normal
samples adjacent to breast cancers, with the PPVs estimated in 306 invasive breast cancers (compared to same 50 normal reference samples). The
number of top-ranked selected DVCs increases along the panels from left to right. PPVs were estimated for hyper-and-hypomethylated DVCs
separately: in the case of hypermethylated (hypomethylated) DVCs, PPV was estimated as the fraction of these CpGs attaining a t-statistic larger (lower)
than 1.96 (P < 0.05) when comparing invasive cancer to normal. b Left panel: for the top 500 DVCs selected using IEVORA (comparing normal breast
samples to normal-adjacent breast tissue), scatterplots compare the DNA methylation values of these sites in the 42 normal adjacent samples (x-axis,
NADJ) to the corresponding DNA methylation values in the matched breast cancers (y-axis, BC). Observe how hypermethylated DVCs tend to exhibit
further increases in DNAm in the breast cancers that are matched to their corresponding normal-adjacent tissue, whereas the opposite is true for
hypomethylated DVCs. Right panel: as left panel, but now plotting the difference in DNAm between the normal-adjacent sample and normals (x-axis,-
NADJ-N) to the corresponding difference in DNAm between the matched breast cancer and normals (BC-N). We note that because each data point
corresponds to 1 CpG site in one patient who provided a normal-adjacent and breast cancer sample, that some of the hypermethylated (hypomethylated)
DVCs may exhibit lower (higher) methylation in some of the normal-adjacent samples compared to the normal state
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associated OR of 0.29, when by random chance the ex-
pected overlap should have been around 961, represent-
ing again a massive underenrichment (one-tailed Fisher
test P < 1e-90, Binomial test P < 1e-100).
Discussion
The data presented here strongly supports the view
that DNA methylation alterations in pre-neoplastic
cells are of an infrequent and hence stochastic nature,
posing a statistical challenge to their identification.
The epigenetic field defects were characterized by
relatively few “outlier” samples exhibiting significant
deviations in DNA methylation (at least 10 % changes
in terms of absolute beta-values) from a normal
ground state. Because of this, average levels in DNAm
were not significantly changed, which is why ordinary
t-tests or their non-parametric equivalents are under-
powered to detect them. This problem is only exacer-
bated by the inherent difficulty to acquire sufficiently
large numbers of normal tissue specimens from
healthy and cancer patients. Thus, since increasing sample
size is unrealistic, statistical methodologies which can
increase the sensitivity of the assay offer the best hope to
identify epigenetic field defects.
In light of this, the results presented here have deep
and far-reaching implications: using two of the largest
available DNA methylation data sets profiling precursor
cancer lesions in two different cancer types, we have
here shown that epigenetic field defects can only be
identified if we adopt a feature selection paradigm based
on differential variability. This substantially strengthens
our previous observations [13, 14] and marks a paradigm
shift for feature selection in the context of epigenetic
field defect studies in cancer.
There are a number of other important observations
that support, directly or indirectly, the statistical and
biological significance of DVCs. First, we have seen that
many of the DVCs defining epigenetic field defects pro-
gress to exhibit more frequent and therefore more
homogeneous deviations in DNA methylation in samples
that are neoplastic or invasive. Thus, the stochastic het-
erogeneity of DNAm deviations seen in pre-neoplastic
lesions gives way to a much more homogeneous and de-
terministic pattern characteristic of neoplasia and cancer
Fig. 5 Types of differential variability. a Simulated examples of different types of DV arising in DNAm studies, with y-axis labelling the DNAm fraction.
The horizontal dashed lines indicate the mean in each phenotype. Phenotype is labelled by a different color. P-values from a t-test (TT), a Wilcoxon rank
sum test (WT) and Bartlett’s test (BT) are given. Bartlett’s test is a test for differential variance. b Real data examples of the types of DV shown in (a). The
horizontal dashed lines indicate the mean in each phenotype. Phenotype is labelled by a different color. N = normal, CIN2 + =cervical intraepithelial
neoplasia of grade 2 or higher (non-invasive), CC = cervical cancer (invasive). P-values from a t-test (TT), a Wilcoxon rank sum test (WT) and Bartlett’s test
(BT) are given. Bartlett’s test is a test for differential variance
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Fig. 6 The dynamics of DV in carcinogenesis and operating characteristics of DV algorithms. a Progression of DV in cervical carcinogenesis. Left
panel depicts the DNAm beta-value of a specific CpG (cg10141715) across different disease stages in cervical carcinogenesis, including cytologically normal
cells which remain normal 3 years later (N- > N), cytologically normal cells which progress to CIN2+ 3 years later (N- > CIN2+), cervical intraepithelial
neoplasia of grade 2 or higher (CIN2+) and cervical cancer. Right panel is a boxplot representation, indicating the P-values from a t-test (TT), Wilcoxon rank
sum test (WT) and Bartlett’s test (BT) between the normal state (N- > N) and each of the other 3 stages. b Relative fractions of type-1a, type-1b and type-2
DVCs in cervical and breast carcinogenesis. DVCs were selected using an FDR threshold of 0.05 on the Bartlett’s test P-value. They were defined to be of
type-2 if the t-test P-value was not significant (P> 0.05). They were defined to be of type-1 if the t-test P-value < 0.05, and of type-1a if the t-test P-value
was more significant than the one from the Bartlett’s test, otherwise defined as type1-b. In the context of the cervix, the reference samples were normal
cervical samples from the corresponding study. In the context of breast, the reference samples were normal breast tissue samples from healthy women.
c Left panel: Barplots of estimated sensitivity (SE) values averaged over 100 simulated runs for a number of different DV algorithms (standard deviations
were small and not shown for convenience). DVCs were selected at an estimated FDR < 0.05. Shown are the overall sensitivities to detect any DVC, and
the corresponding sensitivities to detect particular types of DV. Right panel: Boxplots of the true FDRs for each DV algorithm. Green dashed line indicates
the line FDR= 0.05
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[15]. This is also the reason why ordinary t-tests, which
largely assume homogeneous phenotypes, are perfectly
adequate to identify cancer diagnostic markers [14]. Sec-
ond, DVCs are not enriched for stromal or immune cell
type GO-terms, instead exhibiting enrichment for bind-
ing sites of non cell-type specific TFs, strongly support-
ing the view that they do not reflect mean shifts in
stromal or immune cell-type composition. Such mean
shifts in stromal or immune cell-type composition,
which could well be present in the tissues studied here,
could be picked out by algorithms such as CAM or
ISVA [34, 35], since these algorithms are designed to
identify average shifts. However, given the complexity of
epithelial tissue types [36, 37], we can’t discard that out-
lier DVCs may mark relatively large shifts in the epithe-
lial cell subtype composition of the tissue. Indeed, the
enrichment of DVCs in the matched breast cancers, may
well reflect the proportional increase of the epithelial cell
of origin of the tumour [22]. Third, and related to the
previous point, we have demonstrated that DVCs exhibit
a non-random genomic distribution, mapping preferen-
tially to binding sites of key transcription factors specify-
ing chromatin architecture. Fourth, DVCs identified
using iEVORA are strongly underenriched for cross-
reactive and polymorphic probes identified by Chen et
al. [33]. This shows that such problematic probes are un-
likely to give rise to DVCs, consistent with the view that
DV between phenotypes is a biological feature. Finally,
we have shown elsewhere that DVCs in normal breast
tissue correlate with clinical features such as tumor size
and clinical outcome [22].
Importantly, our statistical analysis also demonstrated
that not all existing DV algorithms are able to identify
epigenetic field defects. Indeed, we have seen that differ-
ent DV algorithms exhibit widely different operating
characteristics (especially power), largely dependent on
the type of DV that is prominent within the carcinogenic
stage under consideration. Thus, DV algorithms which
can recognize heterogeneous DNA methylation outliers
(such as our novel iEVORA algorithm), have the sensi-
tivity to detect epigenetic field defects, whereas DV algo-
rithms which only aim to control the type-1 error rate
(J-DMDV & DiffVar) do not.
Of note, the better performance of iEVORA over the
other DV algorithms was not just restricted to power,
but also applied to the PPV. This is particularly note-
worthy, because in theory, one main limitation of the
Bartlett’s test implemented in iEVORA is the potentially
large type-1 error rate. This explains why in some in-
stances the PPVs were relatively low, e.g. as in the case
of comparing normal to CIN2+ (PPV ~ 0.3), yet import-
antly the PPVs obtained from the other DV algorithms
were generally even lower (Fig. 3a). We stress again that
although the increased sensitivity afforded by iEVORA
comes at the expense of a high FDR (or low PPV), that
this is nevertheless preferable over using tests that yield
zero sensitivity.
With regard to the PPV evaluation framework used in
this manuscript, it is important to clarify a key and sub-
tle point: the t-statistic computed in the independent
data sets (representing more advanced cancer stages) to
assess progression, has nothing to do with the t-statistic
used in the iEVORA algorithm, which is only used to re-
rank DVCs. It is important to realize that the use of a t-
statistic to re-rank significant DVCs in the discovery set
does not bias the PPV performance of iEVORA in the
independent data sets. Indeed, we already previously
showed that selecting and ranking features according to
a t-test in the discovery set would yield worse PPVs in
the independent data sets compared to the PPVs ob-
tained using Bartlett’s test [14]. This indicates that CpGs
exhibiting the most homogeneous changes (i.e. the lar-
gest absolute t-statistics) in the discovery set, are either
not true positives (consistent with the large FDR values),
or they reflect other biological effects which do not ex-
hibit progression in more advanced cancer stages.
It is also worth emphasizing again the scenarios where
we would expect iEVORA to be a useful feature selec-
tion tool. iEVORA is aimed at cancer studies where one
is comparing two normal cellular phenotypes, with one
of the phenotypes representing normal tissue at risk of
neoplastic transformation. The two most common sce-
narios would include normal samples collected in a pro-
spective setting, with a subset of the normal samples
becoming cancerous at a later stage, or a comparison of
normal tissue from healthy individuals to normal tissue
found adjacent to the cancer. Such normal-adjacent tis-
sue is “at risk” of neoplastic transformation, given that
nearby tissue has already undergone transformation. We
stress that iEVORA is not required and may even be
counterproductive in scenarios where one wishes to
identify diagnostic markers between normal and neopla-
sia or between normal and cancer tissue. The tissue be-
ing considered is also an important consideration, since
our data only provides evidence for the biological im-
portance of DNAm outliers in the actual tissue of origin
for the cancer. Prospective or case–control cancer
EWAS studies conducted in a surrogate tissue such as
blood are scenarios where DNAm outliers are probably
not of direct biological relevance to cancer development,
and therefore represent situations where iEVORA is not
appropriate, an observation we already made previously
[14]. Indeed, we stress again that iEVORA has not been
validated in general EWAS conducted in tissues such as
blood, and therefore we advise the reader against its use
in such studies, unless ample independent replication
sets are available which would allow the biological and
statistical significance of DVCs to be established. Even in
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the context of cancer field defect studies, given that the
FDR and type-1 error rate can be high, application of a
tool such as iEVORA is only advisable if independent data
is available. This is a critical point, because DV can be
driven by a whole plethora of factors, including genetic
variation or exposure to unknown environmental factors.
Only by testing DVCs in independent data, can one firmly
establish their biological and statistical significance.
Finally, it is important to contrast the novel statistical
methodology presented here to the feature selection
method used in GWAS: there, one compares allelic fre-
quencies between cases and controls. The direct
analogue of this in EWAS is to search for loci that are
altered as frequently as possible in cases compared to
controls, i.e. to identify genomic sites where the mean
level of DNAm differs as much as possible between the
two phenotypes [38]. As we have seen however, such an
approach is seriously underpowered in cancer studies
where tissue availability is a major obstacle. The novel
feature selection paradigm of DV offers a new dimension
in the context of EWAS, where, in addition to allelic fre-
quency, we also need to take the magnitude of the alter-
ation into consideration. As shown here, infrequent but
bigger changes in DNAm (thus defining outliers) are
more likely to define cancer field defects, than more fre-
quent yet smaller DNAm changes.
Conclusions
In summary, we have here demonstrated that DNA methy-
lation outliers in pre-neoplastic lesions define epigenetic
field defects, marking cells which become enriched in inva-
sive disease and which may therefore contribute casually to
cancer progression. We recommend that studies aiming to
identify epigenetic field defects in pre-neoplastic cells, and
which for cost or logistical reasons may be underpowered,
make use of DV algorithms like iEVORA, which improve
the sensitivity, since this may be preferable over using algo-
rithms which only provide strong control of the type-1
error rate and which therefore lack sensitivity.
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